This systematic review and network meta-analysis incorporated data from 23 trials to evaluate the efficacy and safety of GLP-1/GIP receptor agonists and weekly insulin analogs, focusing on their effects on HbA1c reduction, fasting plasma glucose (FPG), body weight (BW), incidence of hypoglycemia, and adverse events. Here, GCG is linked to Hypoglycemia.